The 5 drugs tracked here made $27.1B of Pfizer’s 2025 revenue (43%) and lose US exclusivity by 2035. Since 2023, Pfizer has closed 2 acquisitions of $1B or more, worth $51.0B in total.
Bars are each drug's 2025 sales as a share of Pfizer’s total revenue ($62.6B). Eliquis and Xtandi are Pfizer's reported alliance and product revenue ($8.0B, $2.2B). Only drugs tracked here are counted, so full exposure can be higher. Tap a bar for the drug's page.
| Closed | Company bought | Value | Area | What it brought | At closing |
|---|---|---|---|---|---|
| Dec 2023 | SeagenSeagen 8-K, December 2023 | $43.0B | Oncology | Four approved cancer drugs (Padcev, Adcetris, Tivdak, Tukysa) and an antibody-drug conjugate pipelineEnterprise value. | Approved product |
| Nov 2025 | MetseraPfizer 10-Q, Q2 2026 | $8.0B | Cardiometabolic | Injectable and oral obesity drugs in clinical trialsPfizer's reported value, including $0.6B for CVRs that could pay up to $2.3B. | Pipeline only |
| 2 deals | $51.0B | ||||
Acquisitions of whole companies worth $1B or more, announced since January 2023. Values are the headline price Pfizer announced, excluding milestone payments unless noted. Licensing deals are not included.
| Area | At risk by 2037 | Acquisitions since 2023 |
|---|---|---|
| Oncology | $6.3B | $43.0B |
| Cardiometabolic | $14.3B | $8.0B |
| Vaccines | $6.5B | – |
Pfizer has the most revenue at risk in cardiometabolic, but has spent the most on acquisitions in oncology. At risk is 2025 sales of tracked drugs losing US exclusivity by 2037; acquisitions are the headline value of deals closed since 2023.
The two figures measure different things. Revenue at risk is what the drugs earned in 2025. A deal's value is what Pfizer paid, not the sales it will bring in. Only one of the 2 companies it bought was already selling an approved product at closing (Seagen); the rest brought pipeline drugs whose sales are years away and may never arrive. So this page shows the two side by side rather than claiming how much of the gap the deals fill.
Revenue: Pfizer FY2025. Drug sales and dates are sourced on each drug's page; each deal links to Pfizer’s announcement or filing in the table above.
See all 45 drugs on the patent cliff →